Physician profile
Yanni Chen
NPI 1437108701
$15,260.20
in general payments reported to CMS, 2019-2025
55 companies · $2,447 in 2025
The $2,447 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,843 · 2020: $2,120 · 2021: $2,544 · 2022: $2,022 · 2023: $2,175 · 2024: $2,109 · 2025: $2,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,647 · Education: $83.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,646.79 |
| Education | $83.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,018.21 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,119.65 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,075.13 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $983.30 | 2021-2025 | Vraylar, Ubrelvy, Rinvoq |
| Otsuka America Pharmaceutical, INC. | $962.80 | 2019-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $891.63 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $686.82 | 2019-2022 | |
| Pfizer INC. | $631.93 | 2019-2025 | |
| Zimmer Biomet Holdings, INC. | $613.40 | 2020 | |
| Janssen Pharmaceuticals, INC | $481.42 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $449.46 | 2019-2025 | Austedo Xr, Ajovy, Austedo |
| Novartis Pharmaceuticals Corporation | $441.58 | 2019-2025 | |
| Allergan, INC. | $430.62 | 2019-2020 | |
| Astellas Pharma US INC | $427.69 | 2019-2025 | Veozah |
| Radius Health, INC. | $322.66 | 2019-2025 | Tymlos |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $273.85 | 2021-2024 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $267.75 | 2022-2025 | |
| Dexcom, INC. | $267.59 | 2021-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $264.98 | 2019-2021 | |
| Lundbeck LLC | $226.08 | 2020-2025 | Rexulti |
| Glaxosmithkline, LLC. | $200.90 | 2021-2025 | Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $162.74 | 2021 | |
| Mylan Specialty L.P. | $162.32 | 2021-2024 | Yupelri |
| Biohaven Pharmaceutical Holding Company Ltd. | $147.41 | 2022 | |
| Pacira Therapeutics, INC. | $143.42 | 2019-2020 | |
| Bioventus LLC | $143.28 | 2019-2024 | Supartz Fx Sodium Hyaluronate, Exogen Ultrasound Bone Healing System |
| Ferring Pharmaceuticals INC. | $123.18 | 2020-2025 | Euflexxa |
| Exact Sciences Corporation | $103.18 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Endo Pharmaceuticals INC. | $99.87 | 2019-2020 | |
| Myriad Women'S Health, INC. | $98.76 | 2023 | Myrisk |
| Takeda Pharmaceuticals U.S.A., INC. | $90.41 | 2019-2023 | Trintellix |
| Nestle Healthcare Nutrition INC. | $85.83 | 2021-2022 | |
| Abbott Laboratories | $75.28 | 2025 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $65.02 | 2020-2022 | |
| Vertex Pharmaceuticals Incorporated | $64.98 | 2025 | |
| Merck Sharp & Dohme LLC | $55.22 | 2019-2021 | |
| Axsome Therapeutics, INC. | $51.23 | 2023-2025 | Auvelity |
| Eisai INC. | $43.37 | 2020-2022 | |
| Amarin Pharma, INC. | $42.10 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.47 | 2022 | |
| Avanir Pharmaceuticals, INC. | $35.23 | 2022 | |
| Fidia Pharma USA INC. | $35.03 | 2023-2024 | Hymovis |
| Collegium Pharmaceutical, INC. | $34.55 | 2023 | Xtampza |
| Neurocrine Biosciences, INC. | $34.11 | 2022 | |
| Orthofix Medical, INC. | $33.84 | 2021-2023 | Physio-Stim |
| Actelion Pharmaceuticals US, INC. | $33.70 | 2020-2023 | Opsumit, Uptravi |
| Pacira Pharmaceuticals Incorporated | $30.73 | 2019 | |
| Heron Therapeutics, INC. | $30.46 | 2024 | Zynrelef |
| Verona Pharma, INC. | $29.23 | 2025 | Ohtuvayre |
| Arbor Pharmaceuticals, INC. | $28.27 | 2021 | |
| Kyowa Kirin, INC. | $23.53 | 2025 | |
| Medtronic, INC. | $23.45 | 2023 | Closurefast |
| Abiomed | $21.77 | 2025 | |
| Corcept Therapeutics | $18.16 | 2025 | Korlym |
| Bardy Diagnostics, INC. | $15.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yanni Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.